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Abstract
Background: To produce a conceptually equivalent Arabic version to the original Self-Administered Chronic
Respiratory Disease Questionnaire with standardized dyspnea domain (CRQ-SAS) and to assess its reliability.
Methods: The study was carried out in two stages: stage I which was the translation of the CRQ-SAS questionnaire
from the English to the Arabic language, and stage II which represented the test-retest reliability for patients
receiving usual care for COPD who were not yet admitted to the pulmonary rehabilitation program.
Results: Forty five patients with stable COPD were enrolled in this study. Strong test-retest reliability was found for
the four domains of the CRQ-SAS, with the intra-class correlation coefficient of 0.97 for each of the domains. The
association between most parameters and the four domains of CRQ-SAS were not found to be statistically
significant, as measured by Pearson correlation. The number of exacerbations was negatively correlated with the
dyspnea domain (correlation = -0.36, p-value = 0.02). The disease duration was negatively correlated with the
domain fatigue (correlation = -0.35, p-value = 0.02). The correlation between FEV1/FVC ratio and emotion domain
was -0.30 (p-value = 0.05). The mastery domain was negatively correlated with FEV1/FVC ratio with a correlation of
-0.27 with borderline statistical significance (p-value = 0.07).
Conclusion: The Arabic translation of the CRQ-SAS was found to be reliable to assess the quality of life among
patients with COPD.
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Background
The concept of quality of life has added a new dimen-
sion to the measurement of modalities outcomes used
in the management of different diseases. Health-related
quality of life (HRQL) is measured by instruments speci-
fically developed to assess the experiences of patients
with diverse diseases [1]. These instruments vary from
general to disease-specific such as Chronic Respiratory
D i s e a s eQ u e s t i o n n a i r e( C R Q )[ 2 , 3 ] .T h eC R Qi sad i s -
ease specific questionnaire utilized to assess HRQL for
chronic respiratory diseases such as chronic obstructive
pulmonary disease (COPD), bronchiectasis, and intersti-
tial lung diseases. It is considered to be valid, precise,
simple to use, and sensitive to change in clinical status
and covers the domains of dyspnea, emotion, fatigue,
and mastery [4-7]. The original CRQ was interviewer
dependent (CRQ-IA) and was made available with both
individualized and standardized dyspnea domain.
Though CRQ-IA helps to avoid missing items and
errors, it has the drawback that it should be admini-
strated by an interviewer and may be time consuming
[3,8]. This has led to the development of the CRQ - Self
Administrated with standardized dyspnea domain
(CRQ-SAS) [9,10]. Respondents were asked to grade
their function in each item using a seven-point likert
scale. The total score for each domain was divided by
the number of items answered, yielding a potential score
of one to seven, with higher numbers representing bet-
ter function. Moreover, Schunemann et al. reported that
CRQ-SAS did not impair validity and proved to have
more responsiveness when compared to CRQ-IA [11].
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million people. The HRQL questionnaires are not yet
widely utilized as an outcome measurement in Arabic
speaking countries. This has raised the need for the
availability of an Arabic version of an HRQL instrument
which is socially and culturally sensitive and acceptable.
Therefore, the objective of this study was to produce a
conceptually equivalent Arabic version to the original
CRQ-SAS with standardized dyspnea domain and to
assess its reliability.
Methods
The study was carried out at King Abdulaziz Medical
City (KAMC), Riyadh, Saudi Arabia, which is a tertiary
care teaching facility of approximately 1000 bed capa-
city. The study was carried out in two stages: stage I
which was the translation of the CRQ-SAS question-
naire from the English to the Arabic language, and stage
II which was the assessment of the test-retest reliability
for patients receiving usual care for COPD who were
not yet admitted to the pulmonary rehabilitation pro-
gram (PR).
Stage I: Translation
The process was commenced by translating the CRQ-
SAS from the source language (English) to the target
language (Arabic). The forward translation was con-
ducted by two certified local translators. Both produced
independent translation form the source to the target
language. Apart from clarification of some medical ter-
minology, the translators have found no difficulty during
translation. After consultation with the translators, the
primary author re-conciliated a first Arabic version that
was considered conceptually equivalent to the source
language. Another two certified translators, who were
blinded to the source documents, carried out the back
translation from Arabic to English. Both produced inde-
pendent translation from the target language (first ver-
sion of CRQ-SAS) to the source language. The primary
author compared the two translations with the source
CRQ-SAS. The back translation version and the original
source document were reviewed by the owner of CRQ-
SAS. Based on the received comments, a final Arabic
version was produced. Finally, a pilot test was carried
out on 5 patients to ensure that the final draft is clear
and understandable. Based on this testing, we have fina-
lized the Arabic version of the CRQ-SAS.
Stage II: Test - retest reliability
The test-retest reliability was conducted at the out-
patient pulmonary clinic and the PR program at the
KAMC-Riyadh. It was carried out by recruiting a total
of 45 patients attending either of the above mentioned
departments. The inclusion criteria were: age ≤ 75 years,
clinical diagnosis of COPD in a stable condition for at
least 4 weeks, the ratio of forced expiratory volume in
one second over forced expiratory volume (FEV1/FVC
ratio) ≤ 70% and FEV1 ≤ 70%, and free of significant
handicapping disease. After signing the informed con-
sent form, patients were interviewed and physically
examined as part of their routine management. The
Arabic version of the CRQ-SAS was initially self-admini-
strated to the patients. The re-test session was arranged
after 3-5 weeks taking in consideration that they were in
a stable clinical condition. Moreover, patients underwent
different standard tests that included: measurement of
FEV1, FVC, FEV1/FVC ratio, residual volume (RV), total
lung capacity (TLC), arterial saturation by pulse oxi-
meter, and the 6-minute walking test (6MWT) as per
American Thoracic Society criteria [12,13]. Pulmonary
function test would normally be done within two weeks
f r o mt h e6 M W Da n dC R Q - S A St oa v o i de x h a u s t i n g
patients. This study received the approval of the insti-
tute review board of King Abdullah International Centre
for Medical Research (KAIMRC), the research arm of
our health organization.
Statistical analysis
The statistical analyses carried for stage II of this study
are presented in this subsection. Data were entered into
the Statistical Package for Social Sciences (SPSS) version
16, which was used for the data management and ana-
lyses. Continuous variables were summarized by calcu-
lating the mean and its standard deviation, whereas
categorical variables were summarized by the number
and percent. Pearson correlation coefficients were calcu-
lated for the different measures of the CRQ-SAS and
the different baseline characteristics. Reliability analysis
was carried out by calculating the intraclass correlation
coefficient for the test-retest reliability of the Arabic ver-
sion of the CRQ-SAS. A value of 0.7 was considered
acceptable both for Crohnbach’s alpha and the intraclass
correlation coefficient.
Results
F o r t yf i v ep a t i e n t sw i t hs t a b l eC O P Dw e r ee n r o l l e di n
this study. Their average age was 63.3 ± 8.8 years and
ranging between 44-75 years. There were 19 female
patients (42.2%) and 26 male patients (57.8%). The aver-
age disease duration was 13.9 years ± 7.1 (range from 4
to 30). The smoking history reflected as the pack-year
was found to be 39.7 ± 35.8 (range from 0 to 150). The
average number of exacerbations over the past 12
months was found to be 3.8 ± 2.5 (range from 1 to 10),
whereas the number of admissions was 1.2 ± 1.4 (range
from 0 to 5). The average body mass index for the sub-
jects was 32.6 ± 9.3 (range from 18.4 to 52.4). The
FEV1,F V C ,a n dF E V 1/FVC ratio were 58.4% ± 15.3
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85), and 61.7 ± 8.8 (range from 38 to 78), respectively.
The total lung capacity was 90.4% ± 14.8 (range from 71
to 145). 6MWD was 226.9 meter ± 99.2 (range from 50
to 400). Finally, pertaining to the medications, it was
found that 41 patients (91.1%) used an inhaled corticos-
teroid agent, 42 (95.6%) used a long acting beta agonist
agent, and 30 (66.7%) used tiotropium bromide.
The time difference between test-retest CRQ adminis-
trations was 4 ± 0.8 weeks. Table 1 presents the intra-
class correlation coefficients, as well as the means and
standard deviations, between the baseline and follow-up
as an assessment of the test-retest reliability. Strong
test-retest reliability was found for the four domains of
the CRQ-SAS, with the correlation coefficient of 0.97
for each of the domains. Figure 1 presents the scatter
Table 1 Intraclass correlation coefficients between baseline and follow-up as an assessment of the test-retest
reliability of the 45 consecutive patients with COPD enrolled in the study (mean ± standard deviation, and range)
Domain Test Score
Mean ± standard deviation
(range)
Re-test Score
Mean ± standard deviation
(range)
Intraclass correlation
Dyspnea 4.9 ± 1.3
(2.4 - 7.0)
5.0 ± 1.3
(2.4 - 6.8)
0.97
Fatigue 4.6 ± 1.1
(2.5 - 6.9)
4.7 ± 1.1
(2.6 - 7.0)
0.97
Emotions 5.0 ± 1.0
(3.2 - 7.0)
5.1 ± 1.0
(3.3 - 7.0)
0.97
Mystery 5.2 ± 1.1
(2.8 - 7.0)
5.3 ± 1.0
(3.0 - 6.9)
0.97
Figure 1 A scatter plot for the responses of the subjects on the 4 domains of the chronic respiratory disease questionnaire.
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of the CRQ-SAS, which indicates high correlation.
Table 2 presents the correlations between selected
parameters and the four domains of CRQ-SAS. Most of
the correlations calculated were not found to be statisti-
cally significant. On the other hand, number of exacer-
bations over the past 12 months was found to be
negatively correlated with the dyspnea domain (correla-
tion = -0.36, p-value = 0.02). The disease duration was
also found to be negatively correlated with the domain
fatigue (correlation = -0.35, p-value = 0.02). The correla-
tion between FEV1/FVC ratio and emotion domain was
-0.30 (p-value = 0.05). Finally, the mastery domain was
also negatively correlated with FEV1/FVC ratio with a
correlation of -0.27, which was found to be of borderline
statistical significance (p-value = 0.07). Both the FEV1
and the 6MWD did not show significant correlation
with any of the domains.
Discussion
The present study confirms that the Arabic version of
the CRQ-SAS performed well and was reliable with a
strong interclass co-relation. Moreover, to the author’s
knowledge, the current study is the first that ever
assessed the quality of life of patients with COPD from
Saudi Arabia. This concept of HRQL was not commonly
practiced in the Middle East as reflected by the scanty
data that came from this region. Its importance rose
from the fact that physiological measures may not
sufficiently assess functional outcomes of interventions
implemented for COPD where HRQL instruments can
serve this purpose [1,3].
The instruments that measure HRQL for COPD could
be either disease specific or general in nature. When
compared to general tools, the disease specific instru-
ments are more responsive and may be more valid to
both clinician and patients [1,7]. An effective instrument
should be valid, interpretable, responsive, and reliable
[14,15]. The CRQ which was developed in 1987 is one
of the most commonly used tools to assess HRQL in
patients with COPD that fulfill the aforementioned cri-
teria [7,13]. Though the original CRQ was simple to
use, it was time consuming as it is interviewer depen-
dent with individualized dyspnea domain. In one study,
t h et i m er e q u i r e dt oc o m p l e t et h eC R Q - S A Sw a s
reduced to half the time required for the CRQ-IA [16].
This is partly related to the standardization of the items
related to the dyspnea domain. The CRQ-SAS is consti-
tuted of 20 items that cover four domains: dyspnoea
with 5 questions, fatigue with 4 questions, emotion with
7 questions, and mastery (Feeling of control over the
disease) with 4 questions. The brevity of the CRQ-SAS
with standardized dyspnea domain was considered to be
an attractive alternative as it is also valid, reliable, and
responsive [10,12].
A valid translation is essential to achieve a HRQL
instrument that functions well in a different environ-
ment from its original setting. This carries more
Table 2 Correlations between the initial score of the four domains of CRQ and selected parameters
Dyspnea* Fatigue* Emotion* Mastery*
Age 0.02 (0.88) 0.07 (0.65) 0.05 (0.75) 0.11 (0.49)
Disease duration -0.23 (0.13) -0.35 (0.02) -0.25 (0.10) -0.09 (0.58)
Number of exacerbations over twelve months -0.36 (0.02) -0.02 (0.88) -0.002 (0.99) -0.07 (0.66)
Number of admissions over twelve months -0.18 (0.23) -0.06 (0.68) -0.03 (0.85) -0.20 (0.18)
Smoking history (Pack-year) -0.04 (0.77) -0.17 (0.26) -0.13 (0.39) -0.20 (0.19)
The percentage of Forced Expiratory volume in one second (FEV1) 0.08 (0.59) 0.18 (0.25) -0.07 (0.64) 0.02 (0.91)
FEV1/FVC ratio -0.02 (0.91) -0.20 (0.19) -0.30 (0.05) -0.27 (0.07)
Six minutes walk distance (meter) -0.02 (0.92) 0.06 (0.69) 0.05 (0.76) -0.05 (0.76)
Body mass index -0.12 (0.45) -0.26 (0.08) -0.10 (0.50) 0.0 (1.00)
*correlation (p value)
Table 3 Comparison of the different studies in the literature that assessed the health related quality by CRQ-SAS and
the current one
Study Year Country FEV1 Dyspnea Fatigue Emotions Mastery
Williams et al [10] 2001 UK 1.13 L 2.4 3.3 4.4 4.2
Puhan et al [12] 2004 Multinational 45.1% 3.6 3.8 4.1 4.25
Schunemann et al [13] 2005 Canada/USA 45.4% 4.1 3.9 4.7 4.6
Oh et al [23] 2009 Korea 52.3% 4.4 4.0 4.6 5.2
Al-Moamary et al (current study) 2009 Saudi Arabia 58.4% 4.9 4.6 5.0 5.2
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trum of domains like CRQ. Arabic Language is spoken
in 21 countries which necessitate paying attention to the
slight differences related to variations in the accents of
various regions. Our translation was adapted to the
region of the six countries of the Gulf Cooperation
Council (Bahrain, Kuwait, Oman, Qatar, Saudi Arabia,
and United Arab Emirates).T h el e n g t h yp r o c e s so f
translating CRQ-SAS to Arabic has resulted in the adap-
tation of a conceptually equivalent Arabic version to the
original CRQ-SAS. The achieved test-retest reliability in
our study reflects stability over time while the strong
internal consistency reflects stability across the items of
each domain. Similar finding were achieved by the
translation of CRQ to other languages like Dutch, Span-
ish, French-Canadian, and Korean [16-19]. When com-
pared to other studies, patients with COPD from Saudi
Arabia were affected by their disease as reflected by
measuring their quality of life by CRQ-SAS (Table 3).
Similar to the findings in the literature, our study
showed lower correlations between CRQ domains with
t h en a t u r eo fC O P Da n dp u l m o n a r yf u n c t i o np a r a -
meters [3,18,20]. In our study, dyspnea was highly corre-
lated to the number of execrations which reflects a
disease that either advanced or poorly controlled
[21,22]. Dyspnea was not linked with pulmonary func-
tion, a finding supported by other studies [17,22]. Fati-
gue domain was highly correlated with disease duration,
while both emotion and mastery domains were corre-
lated with a more severe disease as reflected by FEV1/
FVC ratio. Guell et al found higher correlation between
the last two domains and pulmonary function [17]. The
domains of emotion, fatigue, and mastery were asso-
ciated with anxiety and depression, findings that are
commonly observed in patient with either advanced dis-
ease or longer disease duration. Despite documented
correlation of CRQ-SAS with the 6MWD, our finding
did not show such correlation [10,12,13,23]. A finding
that can be explained with higher FEV1 in our study
when compared to other studies shown in table 3 and
the need to a larger study sample to verify the lack of
correlations.
Finally, we would like to mention some limitations of
the current study. Due to unavailability of a gold stan-
dard test to assess HRQL for patients with COPD by a
valid linguistic translation of similar instruments, this
study was limited to the reliability of the CRQ-SAS and
not extended to assess its validity. Though we belief that
the lack of priori hypotheses can be claimed to conclude
sufficient validity. Moreover, responsive of the Arabic
version of CRQ-SAS to change was not planned in the
design of the study and merit further studies to assess
this aspect.
Conclusion
The Arabic translation of the CRQ-SAS was found to be
reliable among patients with COPD. It can also perform
well to assess their HRQL in a manner similar to the
original CRQ-SAS.
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